Oramed Pharmaceuticals’ (ORMP) Neutral Rating Reiterated at HC Wainwright
HC Wainwright restated their neutral rating on shares of Oramed Pharmaceuticals (NASDAQ:ORMP – Free Report) in a research note issued to investors on Monday, Benzinga reports. HC Wainwright also issued estimates for Oramed Pharmaceuticals’ Q3 2024 earnings at ($0.02) EPS, Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at $0.17 EPS, Q1 2025 earnings at […]
More Stories
The Good News of Economic Growth
By Jeffrey A. Tucker The Trump administration received some very welcome news in the form of third-quarter economic growth. Even...
Taiwan Gets Dec. 25 Off for First Time in Over 2 Decades
By Lily Zhou Residents of Taiwan got Dec. 25 off for the first time in nearly 25 years after lawmakers...
5 Million Christmas Lights Illuminate 19th Century Ohio Grist Mill
By Jeff Louderback CLIFTON, Ohio—With one flip of a switch, 5 million lights transform one of the country’s largest remaining...
Pentagon Partners With xAI Service for Military’s Growing Artificial Intelligence Toolset
By Ryan Morgan The U.S. military is set to expand its artificial intelligence (AI) toolset in a new partnership with...
DOGE Says 14 Contracts Worth $190 Million Canceled
By Tom Ozimek The Department of Government Efficiency (DOGE) said federal agencies terminated or scaled back 14 additional contracts over...
Transportation Department to Spend Nearly $1 Billion Toward Road Safety
By Naveen Athrappully Transportation Secretary Sean P. Duffy has announced almost $1 billion in funding to “make roads safer for...